Dt. Smoot et al., Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori, AM J GASTRO, 94(4), 1999, pp. 955-958
OBJECTIVE: There are limited data available from the United States on the e
ffectiveness of ranitidine bismuth citrate (RBC) plus two antibiotics to tr
eat Helicobacter pylori. Therefore, the following study was undertaken to e
valuate RBC with two antibiotics, which have been used successfully in comb
ination, to treat H. pylori.
METHODS: Adults with and without abdominal symptoms, who had never received
H. pylori eradication therapy, were tested for the presence of H, pylori i
nfection either by in-office rapid serology assays or histology. Positive s
ubjects were administered the C-13-urea breath test. Subjects who had a pos
itive urea breath test were then treated with RBC 400 mg b.i.d., clarithrom
ycin 500 mg b.i.d., and met ronidazole 500 mg b.i.d. for 10 days. Four to 6
wk after completing antibiotics all subjects were asked to return for a se
cond urea breath test to assess treatment success.
RESULTS: Forty-seven of the 50 subjects enrolled into this study completed
the antibiotic regimen and returned for a repeat urea breath test. Thirty-s
even subjects were negative for H. pylori by urea breath test and 10 were p
ositive, resulting in a 79% eradication rate. Seven subjects (14%) stopped
their medication because of side effects. When analysis was performed on th
e 40 subjects who took greater than or equal to 80% of their medication (pe
r-protocol), the eradication rate was 90%.
CONCLUSIONS: The combination of RBC with clarithromycin and metronidazole s
uccessfully treated H. pylori infection after only 10 days of therapy. The
per-protocol eradication rate from this study was similar to that seen with
Food and Drug Administration (FDA)-approved regimens. In conclusion, RBC p
lus clarithromycin and metronidazole should be considered as a first-line t
reatment regimen for H. pylori infection, and may only need to be taken for
a period of 10 days, as opposed to 14 days for FDA-approved regimens. (C)
1999 by Am. Cell. of Gastroenterology.